Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 open-label safety study of Evusheld for COVID-19 pre-exposure prophylaxis in rituximab-treated rheumatology patients
MOH_2022-05-17_010808Phase 4Recruiting
- Sponsor
- דר בראון יולנדה
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by דר בראון יולנדה. Primary endpoints: Safety of single-dose Evusheld and Pharmacokinetics of Evusheld. Started May 2022; status: recruiting.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2022-05-17_010808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-17_010808.